Related Experiment Video
Updated: Jul 25, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Psychotherapeutic Medications Development Program (PMDP)
H J Haigler1, J M Cott, M V Rudorfer
1National Institute of Mental Health, Rockville, MD 20857.
Psychopharmacology Bulletin
|January 1, 1993
Summary
The National Institute of Mental Health's Psychotherapeutic Medications Development Program (PMDP) accelerates new mental illness drug development and enhances existing treatments. It focuses on drug discovery, technology transfer, and clinical evaluation to improve psychiatric medication accessibility.
Area of Science:
- Psychiatry
- Pharmacology
- Drug Development
Background:
- The National Institute of Mental Health established the Psychotherapeutic Medications Development Program (PMDP) in 1990.
- Mental illness treatment relies on effective and accessible psychotherapeutic medications.
Purpose of the Study:
- To improve, enhance, and expedite the development of novel medications for mental illness.
- To augment the therapeutic utility of currently available psychotherapeutic drugs.
- To streamline the entire drug development pipeline from concept to regulatory approval.
Main Methods:
- Implementing a four-initiative strategy: drug discovery and development, technology transfer, and clinical evaluation.
- Facilitating the transfer of research from academic and government entities to the pharmaceutical industry.
- Developing and maintaining capabilities for rigorous clinical evaluation of psychotherapeutic medications.
Main Results:
- The PMDP actively supports the advancement of promising new drug candidates.
- Efforts are directed towards enhancing the clinical effectiveness of existing psychotherapeutic medications.
- The program aims to improve information dissemination and facilitate collaborations for technology transfer.
Conclusions:
- The PMDP plays a crucial role in advancing psychotherapeutic medication development.
- The program's initiatives are designed to overcome barriers in bringing new treatments to patients.
- Successful implementation is expected to lead to improved mental health treatment options.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:25Interpersonal Psychotherapy
Interpersonal psychotherapy (IPT) is a structured, time-limited therapeutic approach initially developed to treat depression. It integrates key concepts from psychodynamic, humanistic, and cognitive-behavioral therapies, making it a uniquely eclectic framework. The therapy is rooted in the interpersonal theories of Adolph Meyer and Harry Stack Sullivan, as well as John Bowlby's attachment theory, and focuses on the interplay between interpersonal relationships and emotional well-being.